Treatment of tumor bearing mice with Mel led to antigen expression on the surface of the A20 cells, uptake of antigens and activation of DCs, and priming of tumor-infiltrating CD8+ T cells, effector memory cells (CD25, CD44, CD621L), and granzyme B. Finally, adoptive transfer of antigen-specific CD4+ T cells into melphalan-treated hosts resulted in their clonal expansion of the T cells, downregulation of PD-1 and Foxp3, upregulation of CD40L, and increased cytokine production, which translated into tumor regression and marked prolongation of mouse survival. The gene discussed is CD8A; the disease is neoplasm.